# Quelling of Excitotoxicity in Acute Stroke With Ketamine

Study · id `cardio:ct-nct03223220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03223220](<https://clinicaltrials.gov/study/NCT03223220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03223220

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT03223220. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT03223220, source copy `cardio:ctgov-nct03223220-2023-12-18`, retrieved 2026-10-26)
- Planned start: 2024-07-01 (anticipated) (ClinicalTrials.gov record NCT03223220, source copy `cardio:ctgov-nct03223220-2023-12-18`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT03223220, source copy `cardio:ctgov-nct03223220-2023-12-18`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT03223220, source copy `cardio:ctgov-nct03223220-2023-12-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03223220, source copy `cardio:ctgov-nct03223220-2023-12-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03223220-2023-12-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Quelling of Excitotoxicity in Acute Stroke With Ketamine
- Acronym: QUEST-KETA
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Ketamine
- Intervention (Other): Normal Saline
- Intervention (Drug): Midazolam injection
- Lead sponsor: Lower Merion Neurology Research Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 9c090758b1aa1d9013fe6a25b2194bec3f212209dd21508be9c2ff44009ed674
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
